Synthetic RORγ agonists regulate multiple pathways to enhance antitumor immunity

Xiao Hu1, Xikui Liu1, Jacques Moisan1, Yahong Wang1, Charles A. Lesch1, Chauncey Spooner1, Rodney W. Morgan1, Elizabeth M. Zawidzka1, David Mertz1, Dick Bousley1, Kinga Majchrzak1, Ilona Kryczek1, Clarke Taylor1, Chad Van Huis1, Don Skalitzky1, Alexander Hurd1, Thomas D. Aicher1, Peter L. Toogood1, Gary D. Glick1, Chrystal M. Paulos1, Weiping Zou1, and Laura L. Carter2

1Lycera Corp, Ann Arbor, MI, USA; 2Medical University of South Carolina, Hollings Cancer Center, Charleston, SC, USA; 3University of Michigan, School of Medicine, Ann Arbor, MI, USA

ABSTRACT
RORγt is the key transcription factor controlling the development and function of CD4+ Th17 and CD8+ Tc17 cells. Across a range of human tumors, about 15% of the CD4+ T cell fraction in tumor-infiltrating lymphocytes are RORγt+ cells. To evaluate the role of RORγt in antitumor immunity, we have identified synthetic, small molecule agonists that selectively activate RORγt to a greater extent than the endogenous agonist desmosterol. These RORγt agonists enhance effector function of Type 17 cells by increasing the production of cytokines/chemokines such as IL-17A and GM-CSF, augmenting expression of co-stimulatory receptors like CD137, CD226, and improving survival and cytotoxic activity. RORγt agonists also attenuate immunosuppressive mechanisms by curtailing Treg formation, diminishing CD39 and CD73 expression, and decreasing levels of co-inhibitory receptors including PD-1 and TIGIT on tumor-reactive lymphocytes. The effects of RORγt agonists were not observed in RORγt−/− T cells, underscoring the selective on-target activity of the compounds. In vitro treatment of tumor-specific T cells with RORγt agonists, followed by adoptive transfer to tumor-bearing mice is highly effective at controlling tumor growth while improving T cell survival and maintaining enhanced IL-17A and reduced PD-1 in vivo. The in vitro effects of RORγt agonists translate into single agent, immune system-dependent, antitumor efficacy when compounds are administered orally in syngeneic tumor models. RORγt agonists integrate multiple antitumor mechanisms into a single therapeutic that both increases immune activation and decreases immune suppression resulting in robust inhibition of tumor growth. Thus, RORγt agonists represent a novel immunotherapy approach for cancer.

Introduction
RORγt, as a master transcription factor, plays a key role in the differentiation and maintenance of Type 17 effector subsets of CD4+ (Th17) and CD8+ (Tc17) T cells, and is also pivotal in the differentiation of IL-17-expressing innate immune cell sub-populations (e.g., subsets of innate lymphoid cells, NK cells, γδT cells, and iNK T cells).1,2 These cells are critical for mediating immune responses against fungi, other microbes and cancer cells and are distinguished from other subsets by their production of cytokines such as IL-17A, IL-17F, GM-CSF and IL-22, and chemokine CCL20.2-5 In addition, RORγt plays a critical role in the generation of mature T cells with diverse TCR for antigen recognition by controlling the survival of thymocytes and TCR recombination at the CD4−CD8− double positive stage.6-7 After T cells mature and emigrate from the thymus, only a small fraction of peripheral blood mononuclear cells (PBMCs) from healthy donors express RORγt. However, this transcription factor can be induced by cytokines such as TGFβ and IL-6.

Existing literature data suggest that Th17 and Tc17 cells can mediate potent and durable tumor growth inhibition when transferred to tumor-bearing animals and their hallmark cytokines such as IL-17A and GM-CSF are associated with improved antitumor effects in some cancers.8-11 Human Th17 cells stimulated with ICOS and re-directed with a chimeric antigen receptor (CAR) construct showed persistent tumor killing activity in mice implanted with human mesothelioma.12,13 However, both anti- and pro-tumors effects have been reported for IL-17A.14 These seemingly inconsistent data may derive from the multi-faceted immune responses associated with Type 17 effector cells while IL-17A, as a single cytokine, may manifest anti- or pro-tumor effects depending on the tumor environment or tumor type.

In this report, we show that activation of RORγt with small molecule, synthetic agonists enhances T cell effector functions and decreases immune suppressive mechanisms, leading to improved antitumor efficacy in adoptive cell therapy (ACT) models and in syngeneic murine tumor models. Thus, RORγt agonists represent a novel approach for next generation cancer immunotherapies.
Results

Identification of synthetic RORγ agonists

Administration of Type 17 immune cells, especially CD8+ Tc17 and CD4+ Th17 cells generates durable antitumor immunity in ACT settings.8-10 This efficacy is associated with enhanced persistence of antitumor cells and robust in vivo cytotoxic activity.10,15 To assess the prevalence of these cells in human cancers, we evaluated the expression of the Type 17 master transcription factor, RORγ, in tumor-infiltrating lymphocytes (TILs) and PBMCs from cancer patients. RORγ+ T cells are present at significantly higher frequencies in tumors compared to blood, suggesting that the tumor microenvironment recruits these cells or promotes their generation (Fig. 1A). The percentage of RORγ+ T cells is similar to that of cells expressing T-bet, the hallmark transcription factor of Th1 cells (Fig. 1A). Interestingly, only a fraction of human T cells from either tumor or tonsil co-expresses both RORγ and IL-17A, while a significant fraction expresses either IL-17A or RORγ alone (Fig. 1B). These data suggest that RORγ and IL-17A may play distinct roles in antitumor immunity.

Given the presence of RORγ+ cells in human tumors and the antitumor effects of Type 17 T cells reported in animal models, we sought to evaluate whether activating RORγ with synthetic agonists would enhance Type 17 T cell differentiation and function and improve their antitumor activity. We identified a series of synthetic agonists of RORγ using a time resolved-fluorescence resonance energy transfer (TR-FRET) assay. This assay detects the ability of a synthetic compound to enhance recruitment of co-activator steroid receptor co-activator 1 (SRC1) to the ligand-binding domain of RORγ and was previously used to identify the cholesterol synthesis precursor desmosterol and desmosterol-sulfate as endogenous RORγ agonists.16

Fig. 1C shows that two synthetic compounds, LYC-53772 and LYC-54143, enhance SRC1 recruitment. Both compounds were more potent and induced higher co-activator recruitment than the endogenous agonist desmosterol. These compounds were further characterized in a cellular reporter assay using a Gal4-RORγ fusion construct.16 To enhance the assay window, the basal activity of RORγ was lowered with a known antagonist, ursolic acid. Under this assay condition, desmosterol did not enhance the reporter activity over the basal activity of RORγ (Fig. S1). In contrast, the two synthetic agonists robustly enhanced the reporter to about 150% of the basal RORγ activity, confirming that they induce stronger activation than the endogenous agonists. LYC-53772 and LYC-54143 are potent RORγ agonists with EC50s of 0.6 ± 0.1 and 0.2 ± 0.1 μM, respectively, in this assay. In addition, neither compound activated closely related nuclear receptors including RORA and RORB (Table S1), suggesting that they selectively activate RORγ.

Effects of synthetic RORγ agonists on Th17, Tc17, and Treg differentiation

To assess whether synthetic agonists can enhance Type 17 differentiation, we tested the effects of LYC-53772 on murine Th17 and Tc17 differentiation. Splenocytes from OT-I (for Tc17) and OT-II (for Th17) mice were cultured in the presence/absence of LYC-53772 with OVA-derived peptides SIINFEKL or ISQAVHAAHAEINEAGR, respectively, and the polarizing cytokines TGFβ and IL-6 for 4 days. Signature cytokines from these cells were analyzed by ELISA and results are shown in Figs. 2A and B. When LYC-53772 was present during Th17 or Tc17 differentiation, levels of secreted IL-17A, IL-17F, and GM-CSF were significantly enhanced. IL-22 was also increased during Th17 differentiation. Tc17 cells, however, did not produce detectable levels of secreted IL-22 under these conditions. Similar effects were observed when mRNA levels of these cytokines were examined and an increase of IL-22 was detected in both Th17 and Tc17 cells (Fig. S2A). The extent of Type 17 differentiation on day 4 was assessed using intracellular staining. LYC-53772 significantly increased the percentage of CD4+ and CD8+ T cells that express IL-17A (from 12.0% to 20.0% for CD4+ and 21.4 to 40.4% for CD8+ T cells). Importantly, RORγ agonists have minimal impact on the expression of the key antitumor cytokine, IFNγ particularly in Th17 cells (Fig. 2B). These data confirm that RORγ agonists enhance Type 17 cell differentiation.

To confirm that the effects of RORγ agonists were specific, splenocytes from C57BL/6 wild type or RORγ (−/−) mice were activated by plate bound anti-CD3 and soluble anti-CD28 antibodies, and polarized with TGFβ and IL-6 in the absence or presence of RORγ agonist LYC-54143. Under these differentiation conditions, elevated IL-17A expression was observed in wild-type cells treated with LYC-54143, while cells from RORγ (−/−) mice did not produce IL-17A and LYC-54143 did not increase IL-17A production (Fig. 2C), validating that the effects of our compounds are mediated by RORγ. In addition, when LYC-54143 was added in Th1 polarization conditions, no IL-17A production was detected and IFNγ was not significantly changed by LYC-54143 treatment (Fig. S2B), suggesting that LYC-54143 selectively modulates signature cytokines in RORγ-expressing Th17 cells.

To test the effects of RORγ agonists on primary human T cells, PBMCs were activated with anti-CD3/28 beads and differentiated under Th17 polarization conditions. IL-17A, IL-17F, and IL-22 were all increased by LYC-54143 (Fig. 2D). This effect was specific for type 17 cytokines only as IFNγ, a signature type 1 cytokine, was not affected by LYC-54143.

Th17 and Treg cells share similar differentiation requirements and their respective transcription factors, RORγ and FOXP3 functionally antagonize each other.17,18 Thus, we hypothesized that activating RORγ would limit Treg differentiation. To test this hypothesis, OT-II splenocytes were differentiated into Treg cells in the presence of TGFβ and IL-2, with or without LYC-53772. As shown in Fig. 2E, the percentage of cells expressing FOXP3 declined significantly from 17% to 6% when treated with the agonist LYC-53772 (Fig. 2E). A reduction of FOXP3 mRNA and an increase of IL-17A mRNA was also observed (Fig. S2C). Similarly, when natural Tregs were removed from human PBMCs and the remaining cells differentiated into FOXP3 expressing cells, the percentages of newly differentiated FOXP3+ cells was also reduced in the presence of RORγ agonist LYC-54143 (Fig. 2F).

Type 17 cells are long-lived with a stem-like molecular signature.10,15 Thus, we predicted that RORγ agonists would improve the survival of Type 17 cells. To test this hypothesis, we differentiated OT-II splenocytes into Th17 cells in the absence or presence of LYC-54143, rested the differentiated
Figure 1. Expression of RORγ in human tumors and identification of RORγ agonists. (A) RORγ+ T cells are present in significant fractions in TILs from various tumor types. Total of 14 tumor samples from colon, ovarian, lung, breast and head and neck cancers. Cells were gated on CD45+CD3+CD4+ /CD8-. Unpaired, two-tailed t-test. Bottom. Flow graph shows an example of staining. (B) Co-staining of IL-17A and RORγt shows partial overlap of RORγ and IL-17A expressing cells. (C) A TR-FRET-based assay was used to show that RORγ agonists increase co-activator recruitment. Each data point represents mean ± standard deviation (SD) of biological triplicates.
cells for 3 days and monitored cell death using 7-AAD by flow cytometry. As shown in Fig. 2G, significantly fewer dead cells were found in the LYC-54143 treated cells, supporting that RORγ agonists improve survival of Type 17 cells.

Overall, activation of primary T cells in the presence of a synthetic RORγ agonist enhances cytokine production, differentiation, and survival of Type 17 T cells and inhibits the formation of FOXP3+ Treg cells. These effects require the presence of RORγ and are consistent with reported functions of RORγ. The enhanced Type 17 effector cells resulting from RORγ agonist treatment are more effective and long-lived, which may provide superior antitumor activity.

**Novel immune modulatory effects of synthetic RORγ agonists in murine Type 17 T cells**

The recent success of immunotherapy with the immune checkpoint inhibitors anti-CTLA-4 and anti-PD-1/PD-L1 has demonstrated the critical roles of these receptors in suppressing antitumor immunity.19,20 Since Type 17 cells have been associated with enhanced antitumor immunity and RORγ is a transcription factor, we next examined if RORγ agonists could modulate the expression of PD-1. T cells isolated from C57/BL6 mouse spleens were subjected to Type 17 differentiation as described above in the presence/absence of...
LYC-54143. Differentiated cells were washed, rested, and re-stimulated with anti-CD3 monoclonal antibody to induce PD-1 expression and examined by flow cytometry. In both Tc17 (Fig. 3A) and Th17 (Fig. S3A) cell populations, a significant reduction of PD-1 cells was observed when LYC-54143 was present during differentiation. When mean fluorescent intensity (MFI) was measured for the whole CD4+ or CD8+ population, there was also a significant reduction, suggesting that the RORγ agonist not only decreases the percentage of PD-1+ cells but also reduces the level of PD-1 on individual cells. The PD-1 suppressing effect of LYC-54143 was lost when T cells from RORγ(-/-) mice were used (Fig. S3B), suggesting an RORγ-dependent reduction. Moreover, the PD-1 level was much higher in RORγ(-/-) T cells (Fig. 3C) compared to wild-type Tc17 cells, further supporting a negative role of RORγ on PD-1 expression. Consistent with the requirement for RORγ to suppress PD-1, Tc0, or Tc1 cells which express very low levels of RORγ, have much higher PD-1 and no significant reduction of %PD-1+ cells was observed in these cells upon agonist treatment (Fig. S3C).
Elevated PD-1 in chronically activated T cells is a molecular signature of exhaustion.\textsuperscript{21} Interestingly, when differentiated Type 17 cells were repetitively re-stimulated with anti-CD3, PD-1 expression continued to increase after each round of stimulation, whereas cells treated with LYC-54143 only during initial differentiation maintained low levels of PD-1 after repetitive TCR stimulation (Fig. 3A). These results suggest that ROR\textgamma-agonist-induced effects are long lasting and resistant to repeated activation and may prevent T cell exhaustion. The reduction of PD-1 has functional consequences. When Type 17 cells were re-stimulated with anti-CD3 in the presence of PD-L1, the proliferation was significantly diminished. However, T cells treated with LYC-53772 were resistant to PD-L1 inhibition, resulting in restoration of their proliferative capacity (Fig. 3B and Fig. S3D).

Type 17 polarizing cytokines TGF\textbeta and IL-6 induce the expression of ectonucleotidases CD73 and CD39, resulting in dampened antitumor effector functions.\textsuperscript{22} It was reported that Th17 cells differentiated with low concentrations of TGF\textbeta together with IL-6 and IL-1\textbeta express lower levels of CD73 and better antitumor activity.\textsuperscript{23} LYC-54143 was assessed for its impact on CD73 expression under both differentiation conditions. Addition of LYC-54143 during Th17 polarization resulted in a significant reduction of CD73 under both high or low TGF\textbeta conditions (Fig. 3D). The decrease of CD73 expression by LYC-54143 depends on the presence of ROR\textgamma (Fig. S3E). Similar reduction of CD39 was also observed (Fig. S3F).

Given the importance of co-inhibitory and co-stimulatory receptors in modulating immune responses,\textsuperscript{19} we also explored if ROR\textgamma agonists could regulate other co-inhibitory and co-stimulatory receptors implicated in antitumor immunity. The results are summarized in Fig. 3E. In addition to PD-1, exposing Type 17 cells to LYC-54143 during differentiation decreased the expression of the co-inhibitory receptors TIGIT, CD160, LAIR1, TIM3, and LAG3. On the other hand, LYC-54143 increased the expression of CD226, CD27, and CD137, co-stimulatory receptors that play important roles in antitumor immunity (Fig. 3E). LYC-54143 did not change the expression of CTLA4 or CD28 suggesting that only certain co-regulatory receptors are regulated by ROR\textgamma. Similar data were obtained using human T cells. Reduction in the percentage of CD4\textsuperscript+ T cells expressing PD-1, CD73, CD160, or LAG3 by LYC-54143 was observed in differentiated human Type 17 T cells using PBMCs from cancer patients as well as healthy donors (Figs. S3G and H). Under our activation and differentiation conditions, no changes in percentages (all >90\%) of cells expressing CD226 were observed. However, in most donors a small but significant increase in CD226 MFI was detected (Figs. S3G and H). These data suggest that the regulation of co-regulatory receptors by ROR\textgamma is largely conserved in human T cells.

Collectively, our data show that activating ROR\textgamma with a synthetic agonist, in a ROR\textgamma-dependent manner, decreases co-inhibitory receptor expression, diminishes expression of CD39 and CD73, enzymes important for generating immunosuppressive, extracellular adenosine, and increases co-stimulatory receptor expression. Taken together, these effects would be expected to drive more robust Type 17 effector immune responses and improve the potential for T cell-mediated tumor inhibition.

Type 17 T cells treated with a synthetic ROR\textgamma agonist enhance cytotoxic activity in vitro and mediate potent antitumor immunity when adoptively transferred into mice with large tumors

Our data suggest that the changes induced by synthetic ROR\textgamma agonists in Type 17 T cells could be mechanistically linked to antitumor effector function. To test if ROR\textgamma agonists would enhance the tumor killing activity of cytotoxic Tc17 cells, OT-I Tc17 effector cells were generated in the presence or absence of LYC-54143, and then titrated onto CFSE-labeled, ovalbumin-expressing EG7 tumor cells. After 5 hours, the number of live EG7 tumor cells was quantified and the percent lysis was calculated. As shown in Fig. 4A, LYC-54143-treated Tc17 cells showed a significant increase in their ability to kill EG7 tumor cells at various effector:target ratios compared to untreated controls.

CAR T cell therapy has shown promising clinical efficacy in clinical trials.\textsuperscript{24} To assess if ROR\textgamma agonists could enhance cytotoxic activity of human cells, we utilized CAR engineered human T cells. Human CD4\textsuperscript+ T cells were activated and polarized to a Th17 phenotype in the presence/absence of ROR\textgamma agonist LYC-54143, and then transduced with a CAR that recognizes mesothelin\textsuperscript{25} and expanded for 10 days. The resulting T cells were mixed with mesothelin-expressing tumor cells and tumor cell lysis was assayed by flow cytometry. As shown in Fig. 4B, LYC-54143-treated CAR T cells from four donors showed improved killing of tumor cells. These data support that ROR\textgamma agonists enhance the cytotoxic activity of human T cells and further suggest that ROR\textgamma agonists could be used to augment the tumor killing efficiency of CAR T cells when added during ex vivo expansion.

Having demonstrated that ROR\textgamma-agonist-treated Tc17 and CAR T cells showed enhanced tumor killing in vitro, we next asked if these cells could confer better tumor regression in vivo after being adoptively transferred into tumor-bearing mice. Thy1.1 OT-I CD8\textsuperscript+ T cells were differentiated into Tc17 in the presence or absence of ROR\textgamma agonists and then equal numbers of cells were transferred into mice with established EG7 tumors. As shown in Fig. 4C, at the cell number used, Tc17 cells generated in the presence of vehicle had no significant effect on tumor growth compared with mice that did not receive tumor-specific T cells. However, when either LYC-53772- or LYC-54143-treated Tc17 cells were transferred, a significant inhibition of tumor growth was evident, confirming that ROR\textgamma agonists enhance the antitumor activity of Tc17 cells in vivo. At the end of the study, when spleens and tumors were examined, the number of transferred Thy1.1\textsuperscript+ T cells was significantly higher in mice receiving ROR\textgamma-agonist-treated Tc17 cells compared with mice receiving vehicle-treated Tc17 cells (Fig. 4D and Fig. S4) despite equal numbers of cells being transferred, suggesting that the ROR\textgamma-agonist-treated cells survive and/or proliferate better than untreated cells after being transferred into tumor-bearing mice. Consistent with the in vitro cytokine data, the percentage of IL-17A-expressing cells among the donor cells was higher in the mice receiving LYC-53772-treated cells (Fig. 4E). In addition, donor Tc17 cells treated with LYC-53772 expressed less PD-1 in both spleen and
tumor more than 2 weeks post-transfer, suggesting that the RORγ agonist exerted long-lasting effects on cytokine production and the expression of co-inhibitory receptors.

Given that enhanced IL-17A expression is maintained in agonist-treated T cells after adoptive cell transfer, we next asked whether IL-17A is required for the efficacy of agonist-treated cells.

CD4+ Trp-1 transgenic T cells and CD8+ Pmel-1 transgenic T cells can recognize tyrosinase-related protein 1 and gp-100, respectively, in B16 melanoma cells and have been used extensively in an adoptive cell transfer setting.8,10 When these transgenic T cells were differentiated under Type 17 polarization conditions in the presence/absence of LYC-54143, mixed at a 1:1 ratio and adoptively transferred into mice bearing B16 melanoma, a significantly better inhibition of B16 tumor growth was observed in mice receiving agonist-treated cells than mice receiving vehicle treated cells (Fig. 4F, Type 17 LYC-54143 IgG vs. Type 17 LYC-54143 IgG; p = 0.0002, Type 17 LYC-54143 IgG vs. Type 17 LYC-54143 Anti-IL-17A; p = 0.77, Type 17 + IgG vs. Type 17 + Anti-IL17A and p = 0.37, Type 17 + Anti-IL17A vs. Type 17 LYC-54143 + Anti-IL17A). Mann–Whitney test.
vehicle-treated cells (Fig. 4F, Type 17 + IgG vs. Type 17 + Anti-IL-17A), suggesting that the antitumor efficacy of LYC-54143-treated cells is at least partially dependent on IL-17A in this model.

Together, these data indicate that ex vivo treatment of T cells with synthetic RORγ agonists induces durable changes that result in better tumor cell killing in vitro and following adoptive transfer. Collectively, our results provide a strong rationale for using RORγ agonists to improve ACT regimens.

**Oral administration of a synthetic RORγ agonist potentiates antitumor immunity**

The data described above demonstrate that in vitro treatment of T cells with synthetic RORγ agonists enhance Type 17 effector functions directly. Thus, we hypothesized that in vivo administration of RORγ agonists to shape the developing antitumor immune response would be beneficial. To test this hypothesis, MC38 colorectal tumor cells were implanted subcutaneously into C57/BL6 mice and 3 days later, LYC-54143 was administered by oral gavage twice daily for 3 to 4 weeks. LYC-54143 was well tolerated and no signs of toxicity were observed. Tumor growth was significantly inhibited in mice receiving LYC-54143 (Fig. 5A, left). In addition, the inhibition of tumor growth translated into longer survival for the tumor-bearing mice compared to mice that received vehicle control (Fig. 5A, right). To investigate the involvement of immune cells, we implanted MC38 cells into SCID.beige mice that lack T, B, and NK cells. As shown in Fig. 5B, when LYC-54143 was administered to MC38-implanted SCID.beige mice, no tumor growth inhibition was observed. These results establish that the antitumor effects of RORγ agonist LYC-54143 are mediated by the immune system.

LYC-54143 was also tested in a second syngeneic tumor model, the 4T1 breast tumor model. This tumor model is resistant to many immunotherapies such as anti-PD-L1 or anti-CTLA-4 when administered as a single agent.26,27 Interestingly, LYC-54143 treatment resulted in significant growth inhibition of subcutaneous 4T1 tumors (Fig. 5C). These data suggest that RORγ agonists likely utilize overlapping but distinct mechanisms from anti-PD-1/PD-L1 or anti-CTLA-4 to control tumor growth in these syngeneic tumor models.

In conclusion, LYC-54143 is efficacious as a single-agent immunotherapy in multiple syngeneic tumor models. Thus, RORγ agonists offer a novel, promising immune therapy approach for the treatment of cancers.

**Discussion**

To understand the roles of Type 17 cells in cancers, we focused on RORγ, the master transcription factor critical for differentiation of Type 17 cells. In various human cancers, CD3+CD4+RORγT+ cells are present at higher frequencies in the TILs than in PBMCs (Fig. 1A), suggesting a role for these cells in antitumor immunity. Similar findings were observed when CD3+CD4+IL-17A+ cells were assayed.11 However, it is important to note that although IL-17A is a direct target of RORγ, its expression is also regulated by other transcription factors such as Runx1, STAT3, and BATF.26 In addition, as a nuclear hormone receptor, RORγT activity is also influenced by endogenous ligands, which are tightly regulated16 and may not be present in some cells. These data are consistent with our observation that IL-17A and RORγT are not co-expressed in all T cells (Fig. 1B). Interestingly, a recent study showed that deficiency of IL-17A but not RORγT is associated with decreased spontaneous intestinal tumorigenesis in the APCμ−/− mouse model,29 suggesting that IL-17A and RORγT may play distinct roles in cancers.

We used a chemical biology approach to explore if enhancing formation of Type 17 T cells with a synthetic ligand that activates RORγT could have effects on antitumor immunity. We identified potent, selective RORγ agonists which were confirmed to selectively increase RORγT target genes and enhance differentiation of Th17 and Tc17 cells (Fig. 2). Signature Type 17 cytokines IL-17A, IL-17F, IL-22, and GM-CSF, and chemokine CCL-20 were increased by agonist treatment. IFNγ, a critical cytokine for T cell effector function in tumors, was not significantly reduced by agonist treatment (Fig. 2B and Fig. S2B). These cytokines and chemokine have been shown to increase antitumor effector T cell functions in various tumor models. For example, IL-17A has been shown to inhibit tumor growth in immune competent mouse models via enhancing the generation of MHC-I and MHC-II antigens and tumor-specific cytotoxic cells.30,31 GM-CSF is known to promote formation of dendritic cells and cancer antigen presentation, and has shown clinical activity in cancer patients either as a systemic agent or vaccine adjuvant.32,33 Thus, a RORγ agonist could potentiate effector T cell functions through the action of these cytokines. Our preliminary data suggest that at least in the B16 adoptive transfer model, IL-17A is important for the antitumor effects of RORγ agonists (Fig. 4F). It will be interesting in future studies to evaluate what roles IL-17A and other cytokines play in mediating the antitumor effects of RORγ agonists across different tumor models.

Tumor cells escape immune surveillance by creating an immunosuppressive microenvironment, which includes the recruitment or generation of CD4+FOXP3+ Treg cells and/or conversion of effector T cells into Treg cells.17,18 enhancing Th17 differentiation with a RORγ agonist results in inhibition of Treg formation (Figs. 2E and F). Our results suggest that a RORγ agonist potentially can shift the balance to favor immune effector Th17 cells over immunosuppressive Treg cells. Notably, there exists a population of immunosuppressive T cells that co-express RORγ and FOXP3.34,35 The potential for RORγ agonists to reduce the immunosuppressive activity of these cells and convert them into Th17 effector cells will be interesting to explore in the context of cancer models.

T cells in the tumor microenvironment are frequently in an “exhausted” state exemplified by their reduced proliferation, cytokine production, and cytotoxic activity. These cells express multiple co-inhibitory receptors such as PD-1, CTLA-4, TIM3, and LAG3. The clinical successes of anti-PD-1 and anti-CTLA-4 suggest that overcoming T cell exhaustion represents a promising therapeutic approach to treat cancers. Here, we show that
RORγ agonists reduce PD-1 expression in both Th17 and Tc17 cells (Fig. 3A). The negative regulation of PD-1 expression by RORγ is also supported by the higher PD-1 expression in RORγ deficient cells (Fig. 3C). In addition, human Th17 cells isolated from tumors have been reported to be almost devoid of PD-1 expression. Collectively, these data suggest that activation of RORγ suppresses PD-1 expression, which would be expected to mitigate PD-L1-mediated inhibition of antitumor responses. Moreover, the negative regulation of PD-1 by RORγ agonists is long lasting as RORγ-agonist-treated cells maintain reduced levels of PD-1 after repeated re-stimulation in the absence of an agonist compound and after being transferred into tumor-bearing mice, suggesting that the RORγ agonist may induce epigenetic changes in the PD-1 locus. In addition to PD-1, RORγ agonists also decrease several other co-inhibitory receptors that are hallmarks of T cell exhaustion. These receptors include TIM3, LAG3, TIGIT, CD160, and LAIR1. Blocking antibodies targeting these molecules are being developed for cancer treatment. Interestingly, one of these co-inhibitory receptors, TIGIT, shares ligands (PVR, PVRL2) with co-stimulatory receptor CD226. TIGIT inhibits while CD226 enhances cytotoxic activity of T cells and NK cells. Since we observed increased cytotoxic activity in agonist treated Tc17 cells (Figs. 4A and B), it is interesting to consider if RORγ agonist could potentiate cytotoxic activity via augmenting CD226 and at the same time reducing TIGIT expression.

In addition to CD226, RORγ agonists also enhance the expression of two other co-stimulatory receptors, CD27 and
CD137 (Fig. 3E). These two co-stimulatory receptors belong to the tumor necrosis factor receptor superfamily (TNFRSF7 and TNFRSF9, respectively, for CD27 and CD137). Activation of these TNFRSF co-stimulatory receptors increases proliferation, survival, and effector functions of T cells.\(^\text{36}\) Agonistic antibodies that activate CD27 and CD137 are in clinical trials for various cancers with anti-CD137 showing promising clinical activity.\(^\text{20,43}\) The reciprocal regulation of co-inhibitory receptors and co-stimulatory receptors suggests that ROR\(^\gamma\)-agonist-treated cells may have a less immune suppressive and more immune active phenotype, which may be further reinforced by the reduced expression of CD39 and CD73, two enzymes that catalyze the formation of immunosuppressive adenosine from extracellular ATP and are being targeted for anticancer immunotherapy.\(^\text{44}\)

Our results show that ROR\(^\gamma\)-agonist-treated Type 17 T cells produced higher levels of multiple inflammatory cytokines and expressed higher levels of co-stimulatory receptors. These immune stimulatory effects coupled with enhanced survival and/or self-renewal suggest that ROR\(^\gamma\) agonist treatment will induce durable immune activation. At the same time, ROR\(^\gamma\) agonist treatment limited Treg development, decreased immune checkpoint receptors and reduced extracellular adenosine formation, thus shifting the balance from immune suppression to immune activation. Collectively these effects translate into a better tumor killing activity both \textit{in vitro} and following adoptive transfer into tumor-bearing animals.

Adoptive T cell therapy involves the \textit{ex vivo} expansion of TILs or CAR T cells followed by infusion of the expanded T cells into patients. Despite early clinical success, many challenges still remain, including the lack of consistent engraftment and long-term survival of transferred T cells.\(^\text{45}\) Yet persistence of transferred T cells correlates with efficacy of ACT.\(^\text{46}\) In addition, under the influence of the immunosuppressive tumor microenvironment, transferred tumor-specific T cells can be converted to suppressive T cells such as Tregs or "exhausted" T cells.\(^\text{36}\) These challenges can dramatically limit the efficacy of ACT. We found that addition of a ROR\(^\gamma\) agonist enhances survival of Type 17 T cells and \textit{in vitro} ROR\(^\gamma\) agonist treatment enhances the persistence of transferred T cells. In addition, ROR\(^\gamma\) agonist treatment limits the conversion of effector T cells into Treg and reduces T cell exhaustion markers to sustain the antitumor function of Type 17 T cells. These results suggest that ROR\(^\gamma\) agonists could be used as an adjuvant to ACT either by addition during the \textit{ex vivo} expansion phase or by administration \textit{in vivo} to augment the effector function and persistence of transferred cells for durable antitumor efficacy.

Using an orally bioavailable compound, LYC-54143, we demonstrated that activation of ROR\(^\gamma\) with a synthetic agonist induced robust antitumor effects in MC38 and 4T1 tumor models in an immune cell-dependent fashion (Fig. 5). These two tumor models have distinct TIL profiles, with abundant T cells in MC38 tumors and predominantly myeloid-derived suppressive cells (MDSCs) in 4T1 tumors. Various suppressive cells including Treg, MDSCs, and tumor-associated macrophages, are present in human tumors. Although we have not fully investigated the efficacy of ROR\(^\gamma\) agonists on tumors with various immune suppressive cells, our data suggest that ROR\(^\gamma\) agonists could be efficacious in tumors with diverse microenvironment, which is consistent with the ability of ROR\(^\gamma\) agonists to impact multiple antitumor mechanisms. Certainly, whether ROR\(^\gamma\) agonists could have therapeutic benefits will need to be determined in clinical trials with cancer patients.

Given that ROR\(^\gamma\) regulates many checkpoint receptors, we also speculate that a ROR\(^\gamma\) agonist will have synergistic or additive effects when combined with other immunotherapies, vaccines, radiation, targeted therapies, or chemotherapies. For instance, anti-CTLA-4 induces ICOS on CD4\(^+\) T cells.\(^\text{47}\) Co-stimulation via ICOS induces ROR\(^\gamma\) expression and enhances Th17 generation.\(^\text{13}\) Thus, combination of a ROR\(^\gamma\) agonist with anti-CTLA-4 may provide better efficacy than either single agent alone.

In summary, we show that ROR\(^\gamma\) agonists decrease immune checkpoint receptor expression, Treg generation, and extracellular adenosine generation while enhancing cytokine production, cytotoxic activity, and co-stimulatory receptor expression, and promoting the long-term survival and self-renewal of T cells. These results provide the rationale for testing a ROR\(^\gamma\) agonist in clinical settings as monotherapy or in combination with a checkpoint inhibitor such as anti-CTLA-4 or anti-PD-1. Overall, by integrating effects on multiple effector pathways, ROR\(^\gamma\) agonists represent a promising immunotherapy approach for the treatment of cancer.

### Materials and methods

**Reagents**

All chemicals were purchased from Sigma, Avanti Polar Lipids, Tocris (R&D Systems) or Enzo Life Sciences. Antibodies used in flow analysis were purchased from eBioscience, Biolegend, or Miltenyi. ROR\(^\gamma\) agonists LYC-53772 and LYC-54143 were synthesized by Lycera. For further description of ROR\(^\gamma\) agonists and their use in cancer therapy, see, for example, international patent application publication WO 2015/131035.

**Cofactor recruitment assay and Luciferase reporter assay**

These two assays were conducted as described previously.\(^\text{16}\)

**Mouse type 17 cell differentiation**

Splenocytes from OT-I or OT-II mice (Jackson Laboratories) were activated with OVA-derived peptides SIINFEKL (50 ng/mL) and ISQAVHAAHAEINEAGR (50 ng/mL), respectively, and polarizing cytokine TGF\(\beta\)\((1.25 \text{ ng/mL})\) and IL-6 (10 ng/mL) for 4 or 5 days. In low TGF\(\beta\) condition, polarizing cytokines are TGF\(\beta\)\((0.25 \text{ ng/mL})\), IL-6 (10 ng/mL), and IL-1\(\beta\) (10 ng/mL). Un-polarized cells (Tc0 or Th0) were stimulated by the corresponding peptide.

Alternatively, splenocytes from C57BL6 mice or ROR\(^\gamma\)\((-/-\)) mice were activated with plate-bound anti-CD3 (2.5 \(\mu\)g/mL), soluble CD28 (0.5 \(\mu\)g/mL), and differentiated into Type 17 cells with either high TGF\(\beta\)\((1.25 \text{ ng/mL})\) and IL-6 (10 ng/mL), or Low TGF\(\beta\)\((0.25 \text{ ng/mL})\), IL-6 (10 ng/mL) and IL-1\(\beta\) (10 ng/mL). In some experiments, pan T cells were isolated from splenocytes using Pan T Cell
Isolation kit (Miltenyi) and used in Type 17 cell differentiation. For Th1 and Th17 differentiation, naïve CD4+ T cells were isolated from splenocytes using naïve CD4+ T Cell Isolation Kit (StemCell), activated by plate-bound anti-CD3 and soluble CD28 as above, and polarized into Th1 (10 ng/mL IL-12, 5 μg/mL anti-IL-4, and 1.25 ng/mL IL-2) or Th17 (1.25 ng/mL TGFβ and 10 ng/mL IL-6).

Treg cells were generated from OT-II splenocytes by OT-II peptide (20 ng/mL) together with TGFβ (5 ng/mL) and IL-2 (2.5 ng/mL) for 4 days. All cytokines used for differentiation were purchased from R&D systems.

IL-17A production was determined using mouse IL-17A ELISA (Mabtech). Type 17 differentiation was assessed by flow cytometer after 5 h of stimulation with PMA (100 ng/mL), ionomycin (1 μg/mL) in the presence of brefeldin A (eBiosciences). Cell surface expression of co-stimulatory and co-stimulatory receptors was analyzed by staining with appropriate labeled antibodies (eBiosciences) directly. Intracellular staining was performed using labeled antibodies after fixation and permeabilization. Data were obtained using a BD FACS-Canto II flow cytometer and analyzed by FACS DIVA software.

For Q-PCR analysis, RNA was isolated from differentiated cells by RNeasy mini kit (Qiagen) and mRNA expression was analyzed in StepOne Plus (Life Technologies) real-time PCR instrument using housekeeping gene β actin and cyclophilin as internal standards.

**Human type 17 cell differentiation**

Human whole blood were obtained from healthy volunteers with written informed consent using protocols approved by Chesapeake Institutional Review Board.

PBMCs, isolated from whole blood using Ficoll centrifugation, were activated with anti-CD3/28 beads (Life Technologies) at 1:1 ratio and polarized into Type 17 cells with human IL-1β (10 ng/mL), IL-6 (10 ng/mL), and IL-23 (10 ng/mL). In some experiments, human recombinant TGFβ (0.5 ng/mL) were added to induce FOXP3 and CD73 expression. After 5 days, cytokine levels in the media were determined using a luminex panel (R&D Systems). Cells were collected for flow cytometry analysis.

PBMCs from cancer patients were purchased from Convant Bio and activated with anti-CD3/28 beads and differentiated as described above.

**PD-L1 inhibition assay**

Splenocytes were differentiated in Type 17 conditions as above. 5 days after differentiation cells were counted and rested overnight in fresh T cell growth media. Cells were then labeled with CFSE (ThermoFisher), stimulated with either anti-CD3/anti-CD28 beads or anti-CD3/anti-CD28 Dynabeads (M-450 tosylactivated) at a concentration of 1 bead/cell, plated at 0.5×10^6 cells/mL in 96-well round bottom plates and incubated at 37°C and 5% CO2 for 7 days. Cell proliferation was analyzed by quantifying the fluorescent intensities of CFSE (cells with low CFSE peaks are proliferating cells).

**In vitro cytotoxicity assays**

Tc17 cells were differentiated in vitro using total splenocytes from OT-I mice (C57BL/6-Tg(TcraTcrb)1100Mjb/J, Jackson Laboratory, #003831), with 50 ng/mL OT-I peptide (SIINFEKL) and 2.5 ng/mL TGFβ and 10 ng/mL IL-6. On day 4, Tc17 effector cells were washed and counted. EG7-OVA cells were labeled with CFSE (10 μM) and counted. Various numbers of Tc17 effector (E) cells were mixed with E.G7-OVA target (T) cells in 96-round bottom plate, to achieve E:T ratio of 30:1, 10:1, 3:1 and 1:1. Mixed cells were incubated for 4 hours at 37°C with 5% CO2, and the lysis activity was calculated by E: T ratio at the end of the experiment.

**CAR generation and flow cytometry-based assay to quantify cytolyis**

Blood samples were obtained from Pennsylvania Plasma. Peripheral blood CD4+ and CD8+ T cells were negatively isolated using an untouched T cell kits (Invitrogen) and cultured under Th17 conditions as previously described. For stimulation, T cells were cultured with activating beads coated with antibodies to CD3 and CD28 (eBioscience) at a 1:1 cell-to-bead ratio and then transduced with a Meso-CAR construct, as described. Target cells (K562 cells expressing mesothelin) were labeled with CFSE and seeded at 50,000 cells/well in 96-well plates. Human Th17/Tc17 cells primed or not with RORγ agonist LYC-54143 and CFSE-labeled target cells were co-cultured at 10:1 Effector:Target ratios for 8 hours. Total cells were stained with 7AAD and anti-CD45 antibody and analyzed on a flow cytometer.

**Animals**

C57/BL6 and Balb/c mice were purchased from Charles River Laboratories. RORγ (−/−) mice were purchased from Jackson Laboratory. All animal experiments were conducted according to institutional animal care and safety guidelines and with IACUC approval at The University of Michigan (NCRC).

**Adoptive cell therapy tumor models**

The EG7-OVA tumor cells (ATCC) are a cell line derived from a C57BL/6 lymphoma cell line EL4 which was engineered to express the neo-antigen ovalbumin. EG7 tumor cells were implanted subcutaneously into the flank of C57/BL6 mice and allowed to grow. In parallel, splenocytes from Thy1.1 OT-I mice were isolated and differentiated into Tc17 cells in vitro using total splenocytes from OT-I mice (C57BL/6-Tg(TcraTcrb)1100Mjb/J, Jackson Laboratory, #003831), with 50 ng/mL OT-I peptide (SIINFEKL) and 2.5 ng/mL TGFβ and 10 ng/mL IL-6. On day 4, Tc17 effector cells were washed and counted. E.G7-OVA cells were labeled with CFSE (10 μM) and counted. Various numbers of Tc17 effector (E) cells were mixed with E.G7-OVA target (T) cells in 96-round bottom plate, to achieve E:T ratio of 30:1, 10:1, 3:1 and 1:1. Mixed cells were incubated for 4 hours at 37°C with 5% CO2, and the lysis activity was calculated by E: T ratio at the end of the experiment.

**B16F10 melanoma cells**

B16F10 melanoma cells were implanted subcutaneously into the flank of C57/BL6 mice. Trp-1 CD4+ cells and Pmel-1
CD8\(^+\) cells were harvested from TRP-1 and Pmel01 mice, differentiated into Type 17 cells in the presence/absence of LYC-54143 (10 \(\mu\)M) and transferred into B16F10 bearing mice as described.\(^8,10\) Neutralization of IL-17A were conducted as described.\(^10\)

**Syngeneic tumor models**

MC38 murine colon carcinoma cells or 4T1 murine breast carcinoma cells (ATCC) were implanted subcutaneously into the flank of C57BL/6 or Balb/c mice, respectively. Three days after implantation, mice were dosed with vehicle (1% Tween 80) or LYC-54143 at 100 mg/kg twice a day. Tumor volume, measurable 10–12 days after implantation, was assessed two to three time weekly using caliper measurement of length and width of tumor. Tumor volume calculation = \(0.5 \times (\text{length} \times \text{width})^2\). SCID.beige mice (Jackson Laboratory) were also used as host mice for MC38 tumor cells to determine the immune system dependence. Mice were taken down after tumor volume reached ethical end point of 2,000 mm\(^3\).

**Data analysis and statistics**

*In vitro* experiments were done with biological replicates higher than or equal to three unless otherwise noted in figure legends. Most critical experiments were conducted at least three times with similar results. Most data presented in figures are mean ± standard deviation (SD) of biological replicates. Statistics for *in vitro* data were done using unpaired, two-tailed \(t\)-test. Statistical comparison of treatment effects involving different human donors were analyzed using paired, two-tailed \(t\)-test. Statistics for *in vivo* data were done using Multiple \(t\)-tests, Mann–Whitney test or Log-rank (Mantel-Cox) test (survival curve) in GraphPad Prism 6.

**Disclosure of potential conflicts of interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

We thank Dr Jeff Wilkins and Dr Bruce Goldsmith for critically reading the manuscript and providing constructive suggestions for revision. We also thank all other members of Lycera Corp for creating and maintaining a productive research environment.

**Funding**

K.M. and I.K. had no conflict of interests. C.M.P. and W.Z. received research funding from Lycera Corp. All other authors were employed by Lycera Corp when this work was conducted.

**References**

1. Cua DJ, Tato CM. Innate IL-17-producing cells: the sentinels of the immune system. Nat Rev Immunol 2010; 10:479-89; PMID:20559526; http://dx.doi.org/10.1038/nri2800
2. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Laflaille JJ, Cua DJ, Littman DR. The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 2006; 126:1121-33; PMID:16990136; http://dx.doi.org/10.1016/j.cell.2006.07.035
3. Codarri L, Gyulveszi G, Tosevski V, Hesse L, Fontana A, Magenat L, Suter T, Becher B. RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 2011; 12:560-7; PMID:21516112; http://dx.doi.org/10.1038/ni.2027
4. Manel N, Unutmaz D, Littman DR. The differentiation of human T (H)-17 cells requires transforming growth factor-\(\beta\) and induction of the nuclear receptor RORgammat. Nat Immunol 2008; 9:641-9; PMID:18454151; http://dx.doi.org/10.1038/ni.1610
5. Dong C. Differentiation and function of pro-inflammatory Th17 cells. Microbes Infect / Institut Pasteur 2009; 11:584-8; PMID:19371793; http://dx.doi.org/10.1016/j.micinf.2009.04.001
6. Sun Z, Unutmaz D, Zou YR, Sunshine MJ, Pierani A, Brenner-Morton S, Mebius RE, Littman DR. Requirement for RORgamma in thymocyte survival and lymphoid organ development. Science 2000; 288:2369-73; PMID:10875923; http://dx.doi.org/10.1126/science.288.5475.2369
7. Guo J, Hawwari A, Li H, Sun Z, Mahanta SK, Littman DR, Krangel MS, He YW. Regulation of the TRC/Rapalpha repertoire by the survival window of CD4(+)/CD8(+) thymocytes. Nat Immunol 2002; 3:469-76; PMID:11967541; http://dx.doi.org/10.1038/ni791
8. Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, Heemskerk B, Wrezinski C, Borman ZA, Muranski P, Restifo NP. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 2009; 114:596-9; PMID:19471017; http://dx.doi.org/10.1182/blood-2009-02-203935
9. Garcia-Hernandez Mde I, Hamada H, Reome JB, Misra SK, Tighe MP, Dutton RW. Adoptive transfer of tumor-specific Tc17 effector T cells controls the growth of B16 melanoma in mice. J Immunol 2010; 184:4215-27; PMID:20237297; http://dx.doi.org/10.4049/jimmunol.0902995
10. Muranski P, Borman ZA, Kerkar SP, Klebanoff CA, Ji Y, Sanchez-Perez L, Sukumar M, Reger RN, Yu Z, Kern SJ et al. Th17 cells are long lived and retain a stem cell-like molecular signature. Immunity 2011; 35:972-85; PMID:22177921; http://dx.doi.org/10.1016/j.immuni.2011.09.019
11. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH et al. Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 2009; 114:1141-9; PMID:19470694; http://dx.doi.org/10.1182/blood-2009-03-208249
12. Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, Lee J, Posey AD, Jr, Scholler J, Scholler N et al. ICOS-based chimeric antigen receptors program bipolar Th17/Th1 cells. Blood 2014; 124:1070-80; PMID:24986688; http://dx.doi.org/10.1182/blood-2013-10-535245
13. Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela-Rohena A, Golovina TN, Carroll RG, Riley JL, June CH. The inducible costimulator (ICOS) is critical for the development of human T(H)-17 cells. J Immunol 2010; 184:5571-8; PMID:20980695; http://dx.doi.org/10.1111/j.1365-2133.2010.04448.x
14. Kryczek I, Zhao E, Liu Y, Wang Y, Vatan L, Szeliga W, Moyer J, Klimczak A, Lange A, Zou W. Human Th17 cells are long-lived effector memory cells. Sci Translational Med 2011; 3:55ra78; PMID:20980695; http://dx.doi.org/10.1126/scitranslmed.3004489
15. Hsu M, Wang Y, Yao LY, Liu X, Lesch CA, Sanchez BM, Welling JM, Morgan RW, Aicher TD, Carter LL et al. Sterol metabolism controls TH17 differentiation by generating endogenous RORgamma agonists. Nat Chem Biol 2015; 11:141-7; PMID:25558972; http://dx.doi.org/10.1038/nchembio.1714
16. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, Weiner HL, Kuchroo VK. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006; 441:235-8; PMID:16684838; http://dx.doi.org/10.1038/nature04753
17. Yang XO, Nurieva R, Martinez GI, Kang HS, Chung Y, Pappu BP, Shah B, Chang SH, Schluns KS et al. Molecular
antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity 2008; 29:44-56; PMID:18585065; http://dx.doi.org/10.1016/j.immuni.2008.05.007

19. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; http://dx.doi.org/10.1038/nrc3239

20. Naidoo J, Page DB, Wolchok JD. Immune modulation for cancer therapy. Br J Cancer 2014; 111:2214-9; PMID:25211661; http://dx.doi.org/10.1038/bjc.2014.348

21. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, Subramaniam S, Blattman JN, Barber DL, Ahmed R. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007; 27:670-84; PMID:17950003; http://dx.doi.org/10.1016/j.immuni.2007.09.006

22. Chalmim F, Mignot G, Bruchard M, Chevriaux A, Vegran F, Hichami A, Ladoire S, Derangere V, Vincent J, Masson D et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression. Immunity 2012; 36:362-73; PMID:22460269; http://dx.doi.org/10.1016/j.immuni.2011.12.019

23. Chatterjee S, Thyagarajan K, Kesarwani P, Song JH, Soloschenko M, Fu J, Bailey SR, Vasu C, Kraft AS, Paulos CM et al. Reducing CD73 expression by IL1beta-Programmed Th17 cells improves immunotherapeutic control of tumors. Cancer Res 2014; 74:6048-59; PMID:25250101; http://dx.doi.org/10.1158/0008-5472.CAN-14-1415

24. Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annual Rev Med 2014; 65:333-47; PMID:24274181; http://dx.doi.org/10.1146/annurev-med-060512-150254

25. Beatty GL, Haas AR, Maus MV, Yamasawa K, Tamura K. Inoculation of human interleukin-17 gene-transfected Meth-A fibrosarcoma cells induces T cell-dependent tumor-specific immunity in mice. Oncology 2001; 61:79-89; PMID:11474253; http://dx.doi.org/10.1159/000055357

26. Benchetrit F, Ciree A, Vives V, Warnier G, Gey A, Sautes-Fridman C, Fossiez F, Haicheur N, Frimand WH, Tartour E. Interleukin-17 inhibits tumor cell growth by means of a T-cell-dependent mechanism. Blood 2002; 99:2114-21; PMID:11877287; http://dx.doi.org/10.1182/blood.v99.6.2114

27. Arelano M, Lonial S. Clinical uses of GM-CSF, a critical appraisal and update. Biologics: Targets Therapy 2008; 2:13-27; PMID:19707424; http://dx.doi.org/10.2147/BTT.S1355

28. Kwek SS, Kah JH, Greaney SK, Lewis J, Cha E, Zhang L, Weber RW, Leonard L, Markovic SN, Fong I et al. GM-CSF and ipilimumab therapy in metastatic melanoma: Clinical outcomes and immunologic responses. Oncoimmunology 2016; 5:e1101204; PMID:27141383; http://dx.doi.org/10.1080/2162402X.2015.1101204

29. Seif E, Geva-Zatorsky N, Oh S, Komnikova L, Zemmour D, McGuire AM, Burzyn D, Ortiz-Lopez A, Lobera M, Yang J et al. Mucosal Immunology: Individual intestinal symbionts induce a distinct population of RORgamma(+) regulatory T cells. Science 2015; 349:993-7; PMID:26272906; http://dx.doi.org/10.1126/science.aab9420

30. Ohnmacht C, Park JH, Cording S, Wing JB, Atarashi K, Obata Y, Gaboriau-Routhiau V, Marques R, Dulauroy S, Fedoseeva M et al. Mucosal Immunology. The microbiota regulates type 2 immunity through RORgamma(+) T cells. Science 2015; 349:989-93; PMID:26160380; http://dx.doi.org/10.1126/science.aac4263

31. Wherry EJ, Kuchri M. Cellular and molecular insights into T cell exhaustion. Nat Rev Immunol 2015; 15:486-99; PMID:26205583; http://dx.doi.org/10.1038/nri3862

32. Anderson AC, Joller N, Kuchroo VK. Lag-3, Tim-3, and TIGIT: Co-inhibitory receptors with specialized functions in immune regulation. Immunity 2016; 44:989-1004; PMID:27912565; http://dx.doi.org/10.1016/j.immuni.2016.05.001

33. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol 2013; 13:227-42; PMID:23470321; http://dx.doi.org/10.1038/nri3405

34. Staniesky N, Simic H, Arapovic J, Toporik A, Levy O, Novik A, Levine Z, Beiman M, Dassa L, Achdout H et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA 2009; 106:17858-63; PMID:19815499; http://dx.doi.org/10.1073/pnas.0903471106

35. Chan CJ, Martinet L, Gilfillan S, Souza-Fonseca-Guimaraes F, Chow MT, Town L, Ritchie DS, Colonna M, Andrews DM, Smyth MJ. The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat Immunol 2014; 15:431-8; PMID:24658051; http://dx.doi.org/10.1038/ni.2850

36. Johnston RJ, Yu X, Grogan JL. The checkpoint inhibitor TIGIT limits antitumor and antiviral CD8+ T cell responses. Oncoimmunology 2015; 4:e1036214; PMID:26405604; http://dx.doi.org/10.1080/2162402X.2015.1036214

37. Lozano E, Dominguez-Villar M, Kuchroo V, Haller DA. The TIGIT/CD226 axis regulates human T cell function. J Immunol 2012; 188:3869-75; PMID:22427644; http://dx.doi.org/10.4049/jimmunol.1103627

38. Sanmamed MF, Pastor F, Rodriguez A, Perez-Gracia JL, Rodriguez-Ruiz ME, Jure-Kunkel M, Melero I. Agonists of co-stimulation in cancer immunotherapy directed against CD137,OX40, GITR, CD27, CD28, and ICOs. Seminars Oncol 2015; 42:640-55; PMID:26320067; http://dx.doi.org/10.1053/j.semincancer.2015.05.014

39. Young A, Mittal D, Stagg J, Smyth MJ. Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discovery 2014; 4:879-88; PMID:25035124; http://dx.doi.org/10.1159/00035124. CD-14-0341

40. Pule MA, Savoldo B, Myers GD, Rossig C, Russell HV, Dotti G, Huls MH, Liu E, Gee AP, Mei Z et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med 2008; 14:1264-70; PMID:18978797; http://dx.doi.org/10.1038/nm.1882

41. Robbins PF, Dudley ME, Wunderlich JR, El-Gamil M, Li YF, Zhou J, Huang J, Powell DJ, Jr, Rosenberg SA. Cutting edge: persistence of transferred lymphocyte clones correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004; 173:7125-30; PMID:15585832; http://dx.doi.org/10.4049/jimmunol.173.12.7125

42. Ng Tang D, Shen Y, Sun J, Wen S, Wolchok JD, Yuan J, Allison JP, Sharma P. Increased frequency of ICOS+ CD4 T cells as a pharmacodynamic biomarker for anti-CTLA-4 therapy. Cancer Immunol Res 2013; 1:229-34; PMID:24777852; http://dx.doi.org/10.1158/2326-6066.CIR-13-0020